Proposal for Tofacitinib

Overview of Therapeutic Candidate –
Tofacitinib is an orally available, synthetic small‐molecule inhibitor that belongs to the group of Janus kinase (JAK) inhibitors. Initially discovered and developed by screening chemical libraries (notably by Pfizer as documented in earlier studies), tofacitinib was designed as an ATP‐competitive inhibitor that preferentially targets JAK1 and JAK3, while also exhibiting partial activity against JAK2 and TYK2. This compound falls under the broader class of kinase inhibitors and is recognized for its capacity to modulate intracellular cytokine receptor signaling through interrupting the JAK/STAT pathway. JAK inhibitors as a class have found widespread use in the treatment of autoimmune and inflammatory conditions, most notably rheumatoid arthritis (RA) and other immune‐mediated diseases. Tofacitinib, marketed as Xeljanz®, has rapidly become a benchmark compound within this class due to its well‐characterized pharmacokinetics, established human safety profile, and demonstrated efficacy in controlling inflammatory processes in disorders where cytokine signaling plays a pivotal role (Tanaka & Yamaoka, 2013).

Therapeutic History –
Tofacitinib’s journey from bench to bedside underscores its robust therapeutic history. It has been extensively studied and approved for use in rheumatoid arthritis, where its anti‐inflammatory properties have been validated through multiple randomized, placebo‐controlled clinical trials. As a drug class, JAK inhibitors have been successfully repurposed for several inflammatory diseases such as psoriatic arthritis, ulcerative colitis, and even refractory dermatomyositis. In particular, open‐label pilot studies in patients with refractory dermatomyositis have demonstrated that tofacitinib leads to significant decreases in interferon‐regulated chemokines and improvements in disease activity measures (Paik et al., 2021). Despite its widespread use in these conditions, there is currently limited clinical trial data directly supporting its use in Inclusion Body Myositis (IBM). Nevertheless, some searches on ClinicalTrials.gov reveal emerging interest in investigating JAK inhibitors including tofacitinib in IBM or related inflammatory myopathies (ClinicalTrials.gov, 2022), suggesting that the drug’s promising profile in autoimmune diseases has naturally led researchers to explore its repurposing for IBM.

Mechanism of Action –
The molecular mechanism of action of tofacitinib is well‐delineated in the literature. Tofacitinib acts as a reversible, ATP‐competitive inhibitor of JAK enzymes, with preferential inhibition of the JAK1 and JAK3 isoforms (Tanaka & Yamaoka, 2013; Krishnaswami, Hodge, & Kawabata, 2016). By binding to the catalytic domain of these kinases, it prevents phosphorylation events that are critical for the activation and dimerization of STAT transcription factors. Once phosphorylated, STAT proteins normally translocate to the nucleus to drive gene transcription of numerous cytokines and inflammatory mediators. Through inhibition of this signaling cascade, tofacitinib effectively suppresses the response to type I interferons as well as other pro‐inflammatory cytokines such as interleukin‐6, interleukin‐2, and interferon‐gamma—all of which have been implicated in the pathogenesis of IBM (Tanaka & Yamaoka, 2013; Traves et al., 2021). In biochemical and cellular studies, the compound has demonstrated an 80–95% inhibition of key cytokine pathways shortly after dosing, underscoring its potent immunomodulatory effects. Furthermore, by reducing STAT phosphorylation, tofacitinib indirectly impacts downstream pathways such as nuclear factor‐kappa B (NF-κB), which is known to play a central role in muscle atrophy and the inflammatory response (Krishnaswami et al., 2016). The JAK/STAT axis is particularly relevant in muscle biology; for instance, type I interferon signaling has been associated with inflammatory myopathies, and its downregulation is considered beneficial in reducing chronic muscle inflammation and catabolic processes (Hou et al., 2021).

Expected Effect –
Based on the central hypothesis, the expected effect of tofacitinib in an IBM therapeutic context is to suppress the deleterious inflammatory milieu observed in IBM muscle. IBM is characterized by a prominent type I interferon signature and chronic inflammation that leads to NF-κB activation, muscle atrophy gene expression, and impaired muscle regeneration. Preclinical studies in various myopathy models—albeit not directly in IBM—have shown that JAK inhibition can restore muscle function, improve calcium handling, and reduce atrophy (Oliver, 2022). Specifically, in myotube co-culture systems exposed to interferon-beta (IFNβ), selective inhibition of the JAK/STAT pathway has been demonstrated to restore proper calcium handling, a key determinant of contractile performance in muscle cells. By inhibiting JAK1/3, tofacitinib is expected to decrease phosphorylation of STAT proteins and subsequently reduce the expression of interferon-stimulated genes that drive muscle catabolism and inflammation. In IBM muscle, such suppression would theoretically reduce NF-κB activation, leading to decreased expression of muscle atrophy-associated genes, and ultimately improve contractile performance. Gene expression analyses in IBM tissues have repeatedly shown upregulation of interferon-related transcripts and other markers of immune activation that are sensitive to JAK inhibition (Hou et al., 2021). Moreover, prior clinical observations in refractory dermatomyositis patients have established that tofacitinib can downregulate interferon-regulated chemokines such as CXCL9 and CXCL10 (Paik et al., 2021), providing further emphasis on its immunomodulatory potential. Hence, in the proposed assay involving IBM myotubes, the anticipated outcome would be a robust decrease in inflammatory signaling, a normalization of atrophy gene expression, and measurable improvement in contractile parameters, thereby making tofacitinib a promising candidate for repurposing in IBM.

Overall Evaluation –
Tofacitinib emerges as a promising therapeutic candidate for Inclusion Body Myositis based on several strengths. First, its established human safety profile and extensive clinical use in rheumatoid arthritis and other inflammatory myopathies provide a significant translational advantage (Tanaka & Yamaoka, 2013; Paik et al., 2021). The oral route of administration and well-documented pharmacokinetics make it an attractive option for chronic diseases such as IBM. Second, the compound’s mechanism of action—which involves reversible, ATP-competitive inhibition of JAK1 and JAK3—directly targets the inflammatory signaling cascades that are implicated in IBM pathogenesis. By attenuating type I interferon signaling and downstream NF-κB activation, tofacitinib is expected to provide both anti-inflammatory and anti-catabolic effects in muscle tissues, potentially ameliorating muscle atrophy and improving contractile performance (Krishnaswami et al., 2016; Traves et al., 2021).

However, there are also notable weaknesses and challenges. Despite promising mechanistic rationales supported by a robust preclinical literature base, direct clinical evidence of tofacitinib’s efficacy in IBM remains limited. The existing clinical trials to date have primarily focused on rheumatoid arthritis and dermatomyositis, with IBM patients either excluded or not specifically studied (ClinicalTrials.gov, 2022). Moreover, IBM encompasses a complex interplay of inflammatory and degenerative processes, and while cytokine signaling is a central feature, the degenerative component (including protein aggregation and inclusion body formation) may not be fully addressed by a drug that primarily modulates immune-mediated pathways. There also remains a degree of uncertainty regarding the long-term effects of JAK inhibition on muscle regeneration, as chronic suppression of cytokine signaling might interfere with normal repair mechanisms under some circumstances (Hou et al., 2021). In addition, while preclinical data in models of rheumatoid sarcopenia and tissue-engineered human skeletal muscle suggest improvements in muscle contractility with tofacitinib treatment (Oliver, 2022), these findings need to be replicated and validated in IBM-specific models before definitive conclusions regarding its efficacy in IBM can be drawn.

In summary, the strengths of tofacitinib include its robust safety record in humans, orally bioavailable formulation, well-characterized JAK1/3 inhibitory mechanism, and evidence from related inflammatory myopathies that supports its potential to suppress deleterious cytokine signaling. These points provide a strong rationale for its repurposing as a novel therapeutic candidate for Inclusion Body Myositis, particularly in the context of reducing type I interferon signaling and improving muscle contractility by counteracting NF-κB–mediated atrophy. On the other hand, the absence of direct clinical data in IBM, uncertainties regarding its long-term impact on muscle regeneration, and the multifactorial nature of IBM pathology serve as important weaknesses that warrant cautious optimism and further investigation. Overall, based on the current biomedical, clinical, and biochemical literature, tofacitinib stands as a promising candidate that merits further preclinical validation in IBM-specific models and eventually carefully designed clinical trials to assess its therapeutic potential in ameliorating muscle atrophy and improving contractile function in patients with Inclusion Body Myositis (Paik et al., 2021; Hou et al., 2021; Traves et al., 2021).

References
ClinicalTrials.gov. (2022). Clinical characteristics and mechanism research of inhibitors of Janus kinase in idiopathic inflammatory myopathies (NCT05400889). Retrieved from https://clinicaltrials.gov/ct2/show/NCT05400889

Hou, C., Periou, B., Gervais, M., Berthier, J., Baba-Amer, Y., Souvannanorath, S., Malfatti, E., Relaix, F., Bencze, M., & Authier, F. J. (2021). Interferon-gamma mediates skeletal muscle lesions through JAK/STAT pathway activation in inclusion body myositis. bioRxiv. https://doi.org/10.1101/2021.12.16.472927

Krishnaswami, S., Hodge, J. A., & Kawabata, T. T. (2016). The mechanism of action of tofacitinib—An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. [Unknown Journal].

Oliver, C. (2022). Tissue-engineered human skeletal muscle model of rheumatoid arthritis for disease modeling and drug testing. [Unknown Journal].

Paik, J. J., Casciola-Rosen, L., Shin, J. Y., Albayda, J., Tiniakou, E., Leung, D. G., Gutierrez-Alamillo, L., Perin, J., Florea, L., Antonescu, C., Leung, S. G., Purwin, G., Koenig, A., & Christopher-Stine, L. (2021). Study of tofacitinib in refractory dermatomyositis: An open-label pilot study of ten patients. Arthritis & Rheumatology, 73, 858–865. https://doi.org/10.1002/art.41602

Tanaka, Y., & Yamaoka, K. (2013). JAK inhibitor tofacitinib for treating rheumatoid arthritis: From basic to clinical. Modern Rheumatology, 23, 415–424. https://doi.org/10.3109/s10165-012-0799-2

Traves, P. G., Murray, B., Campigotto, F., Galien, R., Meng, A., & Di Paolo, J. A. (2021). JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Annals of the Rheumatic Diseases, 80, 865–875. https://doi.org/10.1136/annrheumdis-2020-219012
